| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
135,531,000 |
| Market
Cap: |
257.51(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.47 - $3.22 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Xeris Biopharma Holdings is a pharmaceutical company. Co.'s primary focus is on therapies for patient populations in endocrinology, neurology, and gastroenterology. Co.'s products include: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages two years and older; Keveyis, the U.S. Food and Drug Administration approved therapy for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev (levoketoconazole), a cortisol synthesis inhibitor used for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Green Jeremy |
|
• • • |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
1,745,974 |
1,745,974 |
|
- |
|
| Deutsch Barry M. |
Chief Financial Officer |
• – – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
2,238 |
23,292 |
|
- |
|
| Edick Paul R |
See Remarks |
• • – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
I/I |
13,430 |
13,430 |
|
- |
|
| Prestrelski Steven |
Chief Scientific Officer |
• – – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
37,362 |
489,323 |
|
- |
|
| Johnson Kenneth Erland |
See Remarks |
• – – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
2,245 |
2,245 |
|
- |
|
| Shannon John Patrick Jr |
See Remarks |
• – – |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
8,983 |
8,983 |
|
- |
|
| Palmetto Partners 2015, Lp |
10% Owner |
– – • |
2018-06-25 |
4 |
B |
$15.00 |
$2,250,000 |
D/D |
150,000 |
2,110,061 |
2.45 |
- |
|
| Palmetto Partners 2015, Lp |
10% Owner |
– – • |
2018-06-25 |
4 |
A |
$0.00 |
$0 |
D/D |
1,960,061 |
1,960,061 |
|
- |
|
83 Records found
|
|
Page 4 of 4 |
|
|
0.01 (0.53%) 
